Plasma NfL is associated with mild cognitive decline in patients with diabetes. Issue 3 (13th March 2022)
- Record Type:
- Journal Article
- Title:
- Plasma NfL is associated with mild cognitive decline in patients with diabetes. Issue 3 (13th March 2022)
- Main Title:
- Plasma NfL is associated with mild cognitive decline in patients with diabetes
- Authors:
- Marutani, Noriko
Akamine, Shoshin
Kanayama, Daisuke
Gotoh, Shiho
Yanagida, Kanta
Maruyama, Riki
Mori, Kohji
Miyamoto, Tesshin
Adachi, Hiroyoshi
Sakagami, Yukako
Yoshiyama, Kenji
Hotta, Maki
Nagase, Aki
Kozawa, Junji
Maeda, Norikazu
Otsuki, Michio
Matsuoka, Takaaki
Iwahashi, Hiromi
Shimomura, Iichiro
Murayama, Norihito
Watanabe, Hiroshi
Ikeda, Manabu
Mizuta, Ichiro
Kudo, Takashi - Abstract:
- Abstract: Background: Patients with diabetes are at a higher risk for cognitive decline. Thus, biomarkers that can provide early and simple detection of cognitive decline are required. Neurofilament light chain (NfL) is a cytoskeletal protein that constitutes neural axons. Plasma NfL levels are elevated when neurodegeneration occurs. Here, we investigated whether plasma NfL levels were associated with cognitive decline in patients with type 2 diabetes. Method: This study included 183 patients with type 2 diabetes who visited Osaka University Hospital. All participants were tested for cognitive function using the Mini‐Mental State Examination (MMSE) and the Rivermead Behavioural Memory Test (RBMT). NfL levels were analysed in the plasma and the relationship between NfL and cognitive function was examined. Results: Lower RBMT‐standardized profile scores (SPS) or MMSE scores correlated with higher plasma NfL levels (one‐way analysis of variance: MMSE, P = 0.0237; RBMT‐SPS, P = 0.0001). Furthermore, plasma NfL levels (β = −0.34, P = 0.0005) and age (β = −0.19, P = 0.016) were significantly associated with the RBMT score after multivariable regression adjustment. Conclusions: Plasma NfL levels were correlated with mild cognitive decline which is detected by the RBMT but not the MMSE in patients with type 2 diabetes. This suggests that plasma NfL levels may provide a valuable clinical tool for identifying mild cognitive decline in patients with diabetes.
- Is Part Of:
- Psychogeriatrics. Volume 22:Issue 3(2022)
- Journal:
- Psychogeriatrics
- Issue:
- Volume 22:Issue 3(2022)
- Issue Display:
- Volume 22, Issue 3 (2022)
- Year:
- 2022
- Volume:
- 22
- Issue:
- 3
- Issue Sort Value:
- 2022-0022-0003-0000
- Page Start:
- 353
- Page End:
- 359
- Publication Date:
- 2022-03-13
- Subjects:
- biomarker -- cognitive dysfunction -- dementia -- diabetes mellitus -- neurofilament light chain
Geriatric psychiatry -- Periodicals
618.9768905 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1479-8301 ↗
http://www.blackwell-synergy.com/loi/psy?close=2005 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/psyg.12819 ↗
- Languages:
- English
- ISSNs:
- 1346-3500
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6946.277347
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21313.xml